Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 2.10
Ask: 2.19
Change: 0.035 (1.66%)
Spread: 0.09 (4.286%)
Open: 2.06
High: 2.15
Low: 2.06
Prev. Close: 2.11
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: RA International loss narrows as revenue grows

Thu, 07th Sep 2023 17:07

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Pantheon Resources PLC - London-based oil and gas company focused on onshore operations in the US - Agrees a private placement of 11.9 million shares at a price of GBP0.1878 each for a total USD2.8 million to IPGL Ltd, a long-term shareholder. Pantheon will use the funds to pay the full quarterly bond repayment of the same amount. Therefore, the placement is cash-neutral and should result in materially similar dilution than would have been the case had the company settled the bond repayment in shares.

----------

Immupharma PLC - London-based drug discovery and development company - Further to announcement on August 31, raises GBP130,683 via the issue of around 6.5 million shares at 2 pence each to existing retail investors, in addition to the GBP1.4 million raised in the subscription and direct subscription. Notes Lisa Baderoon, director, subscribed for 1.0 million retail offer shares.

----------

Technology Minerals PLC - London-based battery metals mining and recycling firm - Raises GBP700,000 from a long-term shareholder through the issue of convertible loan notes. The convertible loan notes carry a coupon of 12% for a term of twelve months from issue and are convertible into shares at 1.4 pence each. "The funding will support the company as it continues to advance its exploration assets up the value curve and Recyclus progresses through the commissioning phase at its Li-ion battery recycling plant and moves closer to commercial production," says Alex Stanbury chief executive.

----------

Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Announces further progress from Hikma in the development of ready-to-use injectable medicine AT307, following a recent positive pre-investigational new drug application meeting between Hikma and the US Food & Drug Administration. In January, Arecor transferred all rights and responsibility for future development and commercialisation of AT307 to Hikma as part of an earlier co-development and license agreement. Under this pact, Arecor is eligible to receive development milestone payments in addition to future recurring revenue from royalty payments upon commercialisation. Hikma has communicated to Arecor its intention to continue the development of AT307 in the US using the FDA's 505(b)(2) regulatory pathway. This pathway provides companies with an abbreviated regulatory review process when evidence of safety and clinical efficacy generated for an originator product is deemed suitable to be relied upon in new marketing applications.

----------

Egdon Resources PLC - Reading-based oil and gas explorer and producer - Further to the announcement of August 7, says Egdon, York Energy (UK) Holdings Ltd and Cuadrilla North Cleveland Ltd have executed a fully termed agreement to enable a farm-in and equalisation of interests between the PL81 and PEDL347 licences. Licences will be assigned as follows: Egdon 52.5%, Cuadrilla 25% and York 22.5%. Egdon would be appointed as the operator of the licences. As consideration, Egdon will pay 100% of the costs associated with the planning, drilling, logging, and either short term testing and completion or plugging and abandonment of a well to optimally test the Weaverthorpe prospect.

----------

Canadian General Investments Ltd - closed-end equity fund focused on Canadian firms - Reports net asset value per share at August 31 was USD57.57, resulting in year-to-date and 12-month NAV returns, with dividends reinvested, of 20.9% and 21.6%, respectively. No comparative NAV figure was given.

----------

RA International Group PLC - specialist provider of complex and integrated remote site services - Says in the six months to June 30 revenue rose 4.1% to USD30.4 million from USD29.2 million the year prior. Pretax loss narrowed to USD2.5 million from USD3.4 million with loss per share of 1.4 pence compared to 2.0p the year before. Highlights order book of USD 71 million at June 30, although this was down from USD96 million last year.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
21 Oct 2014 11:19

UK MIDDAY BRIEFING: GKN A Winner As Earnings Season Hits Full Swing

Read more
21 Oct 2014 11:16

Immupharma raises £3.4m as it gears up for Lupuzor Phase III trial

Shares in drug developer Immupharma were higher after confirmation it had raised £3.4m at a premium price to help fund Phase III trials of its lead product candidate Lupuzor, a potential treatment for lupus. The new shares were issued, principally from long-time investor Aviva, at a price of 53p per

Read more
21 Oct 2014 11:00

UK WINNERS & LOSERS: ASOS Back In Style Despite Profit Fall

Read more
20 Oct 2014 06:59

ImmuPharma Gets EUR400,000 Grant In France For Urelix Technology

Read more
5 Oct 2014 13:32

Sunday share tips: BG Group, Genel Energy, Palace Capital

Sell shares of BG Group, Danny Fortson advised in the Sunday Times. Credit Suisse analysts have questioned whether the gas producer's big Australian operation will open on time and have said BG's estimates for its Brazilian oil fields are bigger than those of Petrobas, which leads the development. I

Read more
30 Sep 2014 09:27

ImmuPharma Poised For Phase III Trials Of Lupuzor As Loss As Expected

Read more
27 Jun 2014 12:10

ImmuPharma Forms European Research Team As Part Of Peptides Drive

Read more
16 Jun 2014 10:52

ImmuPharma Granted New US Patent For Nucant Cancer Treatments

LONDON (Alliance News) - ImmuPharma PLC said Monday that it had been granted a US patent for a new "optically pure" version of its Nucant family of cancer treatments, providing it with longer exclusivity over the product, and expanding their potential uses to related conditions such as age-relate

Read more
16 Jun 2014 08:14

Immupharma gains new patents for Nucant treatments

Drug developer Immupharma has improved the patent protection of its Nucant cancer treatments. Immupharma said the US Patent and Trademark Office has granted a notice of allowance for an "optically pure" version of its Nucant family. A similar grant has been obtained from the European Union, Japane

Read more
21 May 2014 13:14

ImmuPharma's patient approach disappoints

Losses from AIM-listed biotech ImmuPharma were less than expected, with the company working hard to commercialise its Lupuzor lupus treatment via phase III clinical trials and new potential partners. Lupuzor has received approval from the US Food and Drug Administration (FDA) to start late-stage t

Read more
21 May 2014 11:45

ImmuPharma Losses Widen As It Accelerates Research And Development

LONDON (Alliance News) - Specialist drug discovery and development company ImmuPharma PLC Wednesday said it losses widened in 2013, as its invests in developing its lupus and cancer treatments. The company posted pretax profit loss of GBP4.4 million for 2013, compared with a GBP4.2 million

Read more
27 Sep 2013 12:23

ImmuPharma Narrows Losses, Developing Lupus Treatment

Read more
27 Sep 2013 10:30

ImmuPharma reports half-year loss

ImmuPharma's shares fell in Friday morning trading as the company reported a half-year loss in line with last year. Losses for the first six months of the year remained unchanged at £1.8m and loss per share held steady at 2.17p. The drug discovery and development company said during the period it

Read more
13 Aug 2013 09:17

Immupharma progresses with cancer treatment trials

ImmuPharma, a drug developer, has reported that its lead cancer programme, IPP-204106, is progressing, and that trials are being conducted at three hospitals across Europe to identify the optimal dose for treating patients. IPP-204106 is 10 times more efficient that the previous Nucant version in p

Read more
28 Jan 2013 16:06

ImmuPharma non-exec reduces stake

Dr Ajay Agrawal, Non-Executive Director of ImmuPharma, sold a stack of shares in the AIM-listed drug company, it was announced Monday. Agrawal traded in 62,169 shares at 57p a time on January 24th, pocketing £35,436 before tax. The deal was announced the same day the group said its key scientific

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.